FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592817296> ?p ?o ?g. }

• W2592817296 abstract "Abstract Abstract 550 Background: Interim FDG-PET performed after 2 chemotherapy courses (PET-2) is the most powerful predictor of treatment outcome in advanced-stage, ABVD-treated HL (AAHL) patients (pts). Whether early therapy intensification in PET-2 positive HL pts improves overall treatment efficacy for all AAHL pts compared to standard ABVD is still unproven. Patients and study design: In the HD 0607 clinical trial (ClinicalTRial.gov identifier 00795613), AHL (stage IIB-IVB) pts prospectively enrolled by 26 Italian and one Israelian institution are treated with 2 ABVD courses and a PET-2 performed afterwards. PET-2+ pts are randomized to either BEACOPP escalated (Be) plus BEACOPP baseline (Bb) (4+4 courses) or Be+Bb (4+4) and Rituximab (R). PET-2 negative pts are treated with 4 additional ABVD and, upon CR achievement, randomized to either consolidation radiotherapy (Rxt) on the sites of initial bulky disease or no further treatment. Primary endpoint is the efficacy and feasibility of the overall therapeutic strategy. All the non-negative PET-2 (nnPET-2), defined as scans without any residual FDG uptake in any site outside the physiological areas of the tracer concentration, are uploaded in a website for blinded independent central review (BICR) by 6 nuclear medicine experts. Scans are interpreted by visual assessment according to the Deauville 5-point scale (5PS). Results: Starting from 07/2008 till 07/2012, 497 AHL pts were consecutively enrolled and 446 scanned with PET-2. 189/446 (42%) PET-2scans, judged as nnPET-2 by the local PET center, underwent review: 92 were adjudged as positive (62 score 4, 30 score 5) and 97 as negative (score 1–3). Altogether, of 446 pts scanned with a PET-2, 92 (20%) resulted positive and 354 (80%) negative. Age, sex, stage III-IV, bulky, extranodal sites or IPS class where equally distributed among PET-2 positive and negative pts.(p>.05). The median time from PET uploading in the website to review was 45.38 hours, (1–119). The BICR yielded a binary concordance rate among pair of reviewers “very good”, ranging from 0.77 to 0.83 (Cohen's k coefficient) and a overall concordance rate of 0.77 (Krippendorf's alpha). In 92 PET-2+ pts, 60 showed a single site of residual uptake in mediastinal (48), laterocervical (4), supraclavear (2), abdominal (3), axillary (1) nodes and in lung (2).In 32 there were ≥ 2 sites of persistent FDG uptake. In 38/40 pts with a positive PET-2 and bulky disease at baseline the residual FDG uptake (singe or multifocal) was seen within the bulky lesion. Overall response to treatment could be assessed in a cohort of 263 pts who had been fully restaged after lymphoma treatment. Forty-one (15%) had a positive and 222 (84%) a negative PET-2 scan. The relative dose intensity (RDI) for Be+Bb ± R and ABVD ± RxT treated pts. was 94.7% and 97.8%, respectively. Among 41 PET-2+ pts CR was achieved in 30 (73%), PR in 1 (2%) Progression or Relapse (Pro/Rel) in 8 (19%) and not evaluable (NE) in 2(5%). Among 222 PET-2- pts. CR was achieved in 212 (95.5%), PR in 2 (1%), Pro/Rel in 6 (3%), NE in 1 (0,5%). Treatment efficacy could be assessed in a cohort of 187 pts. with a complete treatment and a minimum follow-up of 12 months from treatment completion: 27 (15%) with a positive PET-2, treated with Be+Bb ± R and 160 (85%) with a negative PET-2, treated with ABVD ± RxT. The median follow-up from diagnosis was 845 days (101–1345). Among 27 PET-2+ pts, CCR (Continuous CR) was recorded in 22 (81%) Pro/Rel in 5 (18%). Three patients died in CR: 2 for septic shock and one for pneumonia. Among 160 PET-2- pts. CCR was recorded in 146 (91%), Pro/Rel in 9 (5%), Lost of FU (in CR) in 5 (3%). The 1-y PFS was 80.5%, 97.3% and 94.7% for PET-2+, PET-2- p, and for the entire population, respectively. Overall, treatment was well tolerated: 512 Adverse effects were reported: WHO grade 0+1: 453, grade 2: 45. Grade 3 were observed in 12 pts: anemia (2), neutropenia (6), pancytopenia (1), sepsis (1), diverticulitis (1), Vomiting (1). Grade 4 in 2 pts: pneumonia and neutropenia. Conclusions: These preliminary findings suggest that 1) an early switch from ABVD to escalated BEACOPP can be done safely in PET-2 positive pts, with CR achievement in the majority of cases; 2) a centralized online PET scan review system is feasible and allows a real time decision making process, without significant reduction in the RDI administered; 3) 5PS is a reliable interpretation criteria for interim PET scan, with a very good concordance rate among reviewers. Disclosures: No relevant conflicts of interest to declare." @default.
• W2592817296 created "2017-03-16" @default.
• W2592817296 creator A5003232812 @default.
• W2592817296 creator A5011440395 @default.
• W2592817296 creator A5013236194 @default.
• W2592817296 creator A5015840872 @default.
• W2592817296 creator A5022330993 @default.
• W2592817296 creator A5025496065 @default.
• W2592817296 creator A5026242819 @default.
• W2592817296 creator A5026667594 @default.
• W2592817296 creator A5028619240 @default.
• W2592817296 creator A5030934542 @default.
• W2592817296 creator A5034393745 @default.
• W2592817296 creator A5038575336 @default.
• W2592817296 creator A5038898384 @default.
• W2592817296 creator A5039773395 @default.
• W2592817296 creator A5047187911 @default.
• W2592817296 creator A5055401685 @default.
• W2592817296 creator A5057705097 @default.
• W2592817296 creator A5058639394 @default.
• W2592817296 creator A5058765211 @default.
• W2592817296 creator A5059488532 @default.
• W2592817296 creator A5060176180 @default.
• W2592817296 creator A5069410590 @default.
• W2592817296 creator A5071732201 @default.
• W2592817296 creator A5071803772 @default.
• W2592817296 creator A5081254171 @default.
• W2592817296 creator A5083335271 @default.
• W2592817296 creator A5084921812 @default.
• W2592817296 creator A5087990801 @default.
• W2592817296 creator A5090813987 @default.
• W2592817296 date "2012-11-16" @default.
• W2592817296 modified "2023-10-17" @default.
• W2592817296 title "Early Treatment Intensification in Advanced-Stage High-Risk Hodgkin Lymphoma (HL) Patients, with a Positive FDG-PET Scan After Two ABVD Courses – First Interim Analysis of the GITIL/FIL HD0607 Clinical Trial" @default.
• W2592817296 doi "https://doi.org/10.1182/blood.v120.21.550.550" @default.
• W2592817296 hasPublicationYear "2012" @default.
• W2592817296 type Work @default.
• W2592817296 sameAs 2592817296 @default.
• W2592817296 citedByCount "8" @default.
• W2592817296 countsByYear W25928172962013 @default.
• W2592817296 countsByYear W25928172962014 @default.
• W2592817296 countsByYear W25928172962015 @default.
• W2592817296 crossrefType "journal-article" @default.
• W2592817296 hasAuthorship W2592817296A5003232812 @default.
• W2592817296 hasAuthorship W2592817296A5011440395 @default.
• W2592817296 hasAuthorship W2592817296A5013236194 @default.
• W2592817296 hasAuthorship W2592817296A5015840872 @default.
• W2592817296 hasAuthorship W2592817296A5022330993 @default.
• W2592817296 hasAuthorship W2592817296A5025496065 @default.
• W2592817296 hasAuthorship W2592817296A5026242819 @default.
• W2592817296 hasAuthorship W2592817296A5026667594 @default.
• W2592817296 hasAuthorship W2592817296A5028619240 @default.
• W2592817296 hasAuthorship W2592817296A5030934542 @default.
• W2592817296 hasAuthorship W2592817296A5034393745 @default.
• W2592817296 hasAuthorship W2592817296A5038575336 @default.
• W2592817296 hasAuthorship W2592817296A5038898384 @default.
• W2592817296 hasAuthorship W2592817296A5039773395 @default.
• W2592817296 hasAuthorship W2592817296A5047187911 @default.
• W2592817296 hasAuthorship W2592817296A5055401685 @default.
• W2592817296 hasAuthorship W2592817296A5057705097 @default.
• W2592817296 hasAuthorship W2592817296A5058639394 @default.
• W2592817296 hasAuthorship W2592817296A5058765211 @default.
• W2592817296 hasAuthorship W2592817296A5059488532 @default.
• W2592817296 hasAuthorship W2592817296A5060176180 @default.
• W2592817296 hasAuthorship W2592817296A5069410590 @default.
• W2592817296 hasAuthorship W2592817296A5071732201 @default.
• W2592817296 hasAuthorship W2592817296A5071803772 @default.
• W2592817296 hasAuthorship W2592817296A5081254171 @default.
• W2592817296 hasAuthorship W2592817296A5083335271 @default.
• W2592817296 hasAuthorship W2592817296A5084921812 @default.
• W2592817296 hasAuthorship W2592817296A5087990801 @default.
• W2592817296 hasAuthorship W2592817296A5090813987 @default.
• W2592817296 hasConcept C126322002 @default.
• W2592817296 hasConcept C143998085 @default.
• W2592817296 hasConcept C146357865 @default.
• W2592817296 hasConcept C151730666 @default.
• W2592817296 hasConcept C203092338 @default.
• W2592817296 hasConcept C2775842073 @default.
• W2592817296 hasConcept C2776305933 @default.
• W2592817296 hasConcept C2776694085 @default.
• W2592817296 hasConcept C2776755627 @default.
• W2592817296 hasConcept C2779429289 @default.
• W2592817296 hasConcept C2989005 @default.
• W2592817296 hasConcept C535046627 @default.
• W2592817296 hasConcept C61943457 @default.
• W2592817296 hasConcept C71924100 @default.
• W2592817296 hasConcept C86803240 @default.
• W2592817296 hasConceptScore W2592817296C126322002 @default.
• W2592817296 hasConceptScore W2592817296C143998085 @default.
• W2592817296 hasConceptScore W2592817296C146357865 @default.
• W2592817296 hasConceptScore W2592817296C151730666 @default.
• W2592817296 hasConceptScore W2592817296C203092338 @default.
• W2592817296 hasConceptScore W2592817296C2775842073 @default.
• W2592817296 hasConceptScore W2592817296C2776305933 @default.
• W2592817296 hasConceptScore W2592817296C2776694085 @default.
• W2592817296 hasConceptScore W2592817296C2776755627 @default.
• W2592817296 hasConceptScore W2592817296C2779429289 @default.
• W2592817296 hasConceptScore W2592817296C2989005 @default.
• W2592817296 hasConceptScore W2592817296C535046627 @default.
• W2592817296 hasConceptScore W2592817296C61943457 @default.

• next